The pharmaceutical giant Pfizer had recently released a drug, Sutent, that could inhibit FLT3. Sutent was intended for treating kidney cancer, but because of his sequencing, Wartman would become the first person to use it for ALL. Within two weeks of taking the drug, Wartman was in remission. Soon after, he was in good enough shape to receive a bone marrow transplant to ensure that the cancer would not come back in a mutated form. Four years later, Lukas Wartman’s cancer has not returned.
